Arcellx, Inc.
ACLX
Classement en actions
#2781
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Prix de l'action
$115.07
Dernière synchronisation: 2026-05-15
Capitalisation boursière
$6.73B
Changement (1 jour)
0.00%
Changement (1 an)
32.28%
Pays
US
Échange Arcellx, Inc. (ACLX)
Catégorie
Healthcare
EPS pour Arcellx, Inc. (ACLX)
EPS au December 2025 TTM : $-4.07
Selon les derniers rapports financiers et le cours de l'action de Arcellx, Inc., l’EPS actuel de la société (TTM) est de $-4.07. À la fin de 2023, la société avait un EPS de $-1.47 une diminution par rapport à celui de 2022, qui était de $-4.28.
Historique de l'EPS de Arcellx, Inc. de 2018 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-4.07 | 103.50% |
| 2024 | $-2.00 | 36.05% |
| 2023 | $-1.47 | -65.65% |
| 2022 | $-4.28 | 120.62% |
| 2021 | $-1.94 | 31.97% |
| 2020 | $-1.47 | 182.69% |
| 2019 | $-0.52 | -98.96% |
| 2018 | $-50.17 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -525.55% |
US
|
|
| $-7.98 | 96.07% |
US
|
|
| $-5.29 | 29.98% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -781.57% |
NL
|
